KR20180010345A - 면역억제성 수지상 세포를 얻는 방법 - Google Patents

면역억제성 수지상 세포를 얻는 방법 Download PDF

Info

Publication number
KR20180010345A
KR20180010345A KR1020187002019A KR20187002019A KR20180010345A KR 20180010345 A KR20180010345 A KR 20180010345A KR 1020187002019 A KR1020187002019 A KR 1020187002019A KR 20187002019 A KR20187002019 A KR 20187002019A KR 20180010345 A KR20180010345 A KR 20180010345A
Authority
KR
South Korea
Prior art keywords
mammalian subject
monocytes
platelets
dendritic cells
blood sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020187002019A
Other languages
English (en)
Korean (ko)
Inventor
카르스텐 헨코
귄터 바우어
저스틴 덕워쓰
에이드리언 헤이데이
리차드 에델슨
로버트 티겔라
마이클 지라디
Original Assignee
트랜스이뮨 아게
예일 유니버시티
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 트랜스이뮨 아게, 예일 유니버시티 filed Critical 트랜스이뮨 아게
Publication of KR20180010345A publication Critical patent/KR20180010345A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • C12N5/064—Immunosuppressive dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/15—Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cells; Myeloid precursor cells; Antigen-presenting cells, e.g. dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/418—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/115—Platelets, megakaryocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C12N2506/115—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells from monocytes, from macrophages
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2521/00—Culture process characterised by the use of hydrostatic pressure, flow or shear forces
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2529/00—Culture process characterised by the use of electromagnetic stimulation
    • C12N2529/10—Stimulation by light

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020187002019A 2013-01-03 2014-01-02 면역억제성 수지상 세포를 얻는 방법 Ceased KR20180010345A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361748550P 2013-01-03 2013-01-03
GB1300052.6 2013-01-03
US61/748,550 2013-01-03
GBGB1300052.6A GB201300052D0 (en) 2013-01-03 2013-01-03 Method for obtaining immuno-suppressive dendritic cells
PCT/EP2014/050012 WO2014106631A1 (en) 2013-01-03 2014-01-02 Method for obtaining immuno-suppressive dendritic cells

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020157020667A Division KR20150122639A (ko) 2013-01-03 2014-01-02 면역억제성 수지상 세포를 얻는 방법

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020207025108A Division KR20200106217A (ko) 2013-01-03 2014-01-02 면역억제성 수지상 세포를 얻는 방법

Publications (1)

Publication Number Publication Date
KR20180010345A true KR20180010345A (ko) 2018-01-30

Family

ID=47747914

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020187002019A Ceased KR20180010345A (ko) 2013-01-03 2014-01-02 면역억제성 수지상 세포를 얻는 방법
KR1020157020667A Ceased KR20150122639A (ko) 2013-01-03 2014-01-02 면역억제성 수지상 세포를 얻는 방법
KR1020207025108A Ceased KR20200106217A (ko) 2013-01-03 2014-01-02 면역억제성 수지상 세포를 얻는 방법

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020157020667A Ceased KR20150122639A (ko) 2013-01-03 2014-01-02 면역억제성 수지상 세포를 얻는 방법
KR1020207025108A Ceased KR20200106217A (ko) 2013-01-03 2014-01-02 면역억제성 수지상 세포를 얻는 방법

Country Status (12)

Country Link
US (2) US20160130552A1 (cg-RX-API-DMAC7.html)
EP (2) EP3719118A1 (cg-RX-API-DMAC7.html)
JP (3) JP2016509474A (cg-RX-API-DMAC7.html)
KR (3) KR20180010345A (cg-RX-API-DMAC7.html)
CN (2) CN104955940A (cg-RX-API-DMAC7.html)
AU (1) AU2014204346B2 (cg-RX-API-DMAC7.html)
CA (1) CA2897113C (cg-RX-API-DMAC7.html)
DK (1) DK2941484T3 (cg-RX-API-DMAC7.html)
ES (1) ES2795927T3 (cg-RX-API-DMAC7.html)
GB (1) GB201300052D0 (cg-RX-API-DMAC7.html)
PL (1) PL2941484T3 (cg-RX-API-DMAC7.html)
WO (1) WO2014106631A1 (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013059343A1 (en) 2011-10-17 2013-04-25 Massachusetts Institute Of Technology Intracellular delivery
US10124336B2 (en) 2013-08-16 2018-11-13 Massachusetts Institute Of Technology Selective delivery of material to cells
GB201413665D0 (en) * 2014-07-03 2014-09-17 Transimmune Ag And Yale University Method for obtaining globally activated monocytes
CN122564053A (zh) 2014-10-31 2026-08-14 麻省理工学院 递送生物分子至免疫细胞
WO2016077761A1 (en) 2014-11-14 2016-05-19 Massachusetts Institute Of Technology Disruption and field enabled delivery of compounds and compositions into cells
AU2016206870B2 (en) 2015-01-12 2022-02-17 Massachusetts Institute Of Technology Gene editing through microfluidic delivery
GB201513278D0 (en) * 2015-07-03 2015-09-09 Transimmune Ag And Yale University Device and method for obtaining immunostimulatory antigen-presenting cells
JP6925984B2 (ja) 2015-07-09 2021-08-25 マサチューセッツ インスティテュート オブ テクノロジー 無核細胞への物質の送達
US10946095B2 (en) 2015-09-02 2021-03-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Antibodies specific to human T-cell immunoglobulin and ITIM domain (TIGIT)
EP3518942A4 (en) * 2016-09-29 2020-05-27 Hadasit Medical Research Services&Development Ltd. DENDRITIC CELL PREPARATIONS, COMPOSITIONS AND METHODS OF USE
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
CN109701019B (zh) * 2019-01-04 2021-07-16 中国人民解放军第二军医大学 一种新的长链非编码RNA即lnc-Dpf3、其序列、免疫效应及用途
BR112021013193A2 (pt) 2019-01-07 2021-09-28 Shattuck Labs, Inc. Proteínas heterodiméricas para modulação de células t gama delta
KR102904431B1 (ko) * 2021-05-07 2025-12-26 (주)나노팬텍 수지상 세포의 배양 방법
WO2023283514A1 (en) * 2021-07-06 2023-01-12 Vanderbilt University Fluid shear stress for ex vivo activation of immune effector cells
EP4376860A1 (en) 2021-07-29 2024-06-05 Transimmune AG Methods for selectively reducing immunogenicity in a transplant
US20250375477A1 (en) * 2021-07-29 2025-12-11 Transimmune Ag Selective tolerization - methods of selectively generating tolerogenic dendritic cells
CN121335708A (zh) 2023-05-01 2026-01-13 耶鲁大学 用于疫苗接种的抗原特异性生理性树突状细胞
JP2026516460A (ja) 2023-05-01 2026-05-25 エール・ユニバーシティ 療法用の抗原特異的生理的樹状細胞
CN118256609B (zh) * 2024-02-06 2024-08-30 湖北文理学院 Tm9sf1标志物在监测自身免疫性疾病病程中的应用
WO2026074195A1 (en) 2024-10-05 2026-04-09 Yale University Cytokine loaded activated dendritic cells
WO2026074196A1 (en) 2024-10-05 2026-04-09 Yale University Checkpoint inhibitor loaded activated dendritic cells

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000062818A1 (en) 1999-04-20 2000-10-26 Richard Leslie Edelson Differentiation of monocytes into functional dendritic cells
US8524495B2 (en) * 2007-05-16 2013-09-03 Yale University Methods for inducing the differentiation of blood monocytes into functional dendritic cells
EP2358739A1 (en) * 2008-11-18 2011-08-24 The University Of Queensland Peptide conjugates for suppressing an immune response, methods of making and uses therefor

Also Published As

Publication number Publication date
GB201300052D0 (en) 2013-02-20
AU2014204346B2 (en) 2017-08-31
EP2941484B1 (en) 2020-03-04
JP2018046837A (ja) 2018-03-29
US20160130552A1 (en) 2016-05-12
JP6599958B2 (ja) 2019-10-30
JP2016509474A (ja) 2016-03-31
HK1210626A1 (en) 2016-04-29
CA2897113C (en) 2024-03-12
PL2941484T3 (pl) 2020-10-05
US20220259556A1 (en) 2022-08-18
CN104955940A (zh) 2015-09-30
JP6804607B2 (ja) 2020-12-23
ES2795927T3 (es) 2020-11-25
KR20150122639A (ko) 2015-11-02
DK2941484T3 (da) 2020-06-02
JP2020018315A (ja) 2020-02-06
EP2941484A1 (en) 2015-11-11
WO2014106631A1 (en) 2014-07-10
CA2897113A1 (en) 2014-07-10
CN114410581A (zh) 2022-04-29
AU2014204346A1 (en) 2015-07-02
KR20200106217A (ko) 2020-09-11
EP3719118A1 (en) 2020-10-07

Similar Documents

Publication Publication Date Title
KR102362647B1 (ko) 전반적으로 활성화된 단핵구를 수득하는 방법
AU2020270508B2 (en) C/EBP alpha short activating RNA compositions and methods of use
KR20180128993A (ko) 면역자극성 수지상 세포를 얻는 방법
KR20200106217A (ko) 면역억제성 수지상 세포를 얻는 방법
AU2017267184B2 (en) Method for assessing a prognosis and predicting the response of patients with malignant diseases to immunotherapy
CN114176043B (zh) 用于治疗疾病的遗传修饰的细胞、组织和器官
KR102301464B1 (ko) 종양 세포에 의한 면역 억제를 감소시키기 위한 방법 및 조성물
ES2744098T3 (es) Composiciones y sus usos dirigidos a la huntingtina
KR20210138587A (ko) 개선된 면역요법을 위한 조합 유전자 표적
KR102149483B1 (ko) 예측변수 인자들을 이용하여 동정된 환자 부분 모집단에서 암 치료를 위한 마시티닙의 용도
KR20230034198A (ko) 종양 침윤 림프구의 활성화 및 확장 방법
KR102424991B1 (ko) 타우 발현 조절 조성물
CN115003387A (zh) 用于活化和扩增肿瘤浸润淋巴细胞的方法
AU2016364667A1 (en) Materials and methods for treatment of Alpha-1 antitrypsin deficiency
KR20120082906A (ko) 자가포식현상-향상 유전자 생성물의 조절을 통한 자가포식현상의 조절 방법
KR20170092692A (ko) 질환을 치료하기 위한 유전적으로 변형된 세포, 조직 및 장기
KR20160027968A (ko) Foxp3 발현을 조절하기 위한 조성물 및 방법
KR20220012230A (ko) 스플라이싱 및 번역을 조절하기 위한 방법 및 조성물
KR20040065524A (ko) 백혈병을 검사 및 치료하는 방법
KR20250021378A (ko) 단일유전자성 신경발달 장애 치료를 위한 조성물 및 방법
US20020137077A1 (en) Genes regulated in activated T cells
US12478665B2 (en) Cancer vaccine compositions and methods for using same to prevent and/or treat cancer
KR20190126812A (ko) 질환 진단용 바이오마커
CN100516876C (zh) 用于诊断肾细胞癌(rcc)和其他实体瘤的方法
WO2025260064A1 (en) Gene targets discovered through in vivo crispr activation screens to improve t cell products

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

X091 Application refused [patent]
T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PX0601 Decision of rejection after re-examination

St.27 status event code: N-2-6-B10-B17-rex-PX0601

X601 Decision of rejection after re-examination
T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

P22-X000 Classification modified

St.27 status event code: A-2-2-P10-P22-nap-X000

R18 Changes to party contact information recorded

Free format text: ST27 STATUS EVENT CODE: A-3-3-R10-R18-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000